5 research outputs found
Hanging donor lungs give good shortâ, midâ and longâterm results in lung transplantation
International audienceAbstract Background Hanging donors are considered as marginal donors and frequently unsuitable for lung transplantation. However, there is no evidence of higher lung transplantation (LTx) morbidityâmortality with lungs providing by hanging donor. Methods Between January 2010 and July 2015, we performed a retrospective study at Foch hospital. We aimed to assess whether hanging donor grafts are suitable for lung transplantation. Results A total of 299 LTx were performed. Subjects were allocated to a hanging group (HG) (n = 20) and a control group (CG) (n = 279). Donor and recipient characteristics did not differ. Primary graft dysfunction (PGD) at 72 hours was comparable in both groups ( P = .75). The median duration of postoperative mechanical ventilation (1 [range, 0â84] vs 1 [range, 0â410] day, P = .35), the hospital length of stay (31 days [20â84] vs 32 days [12â435], P = .36) did not differ between the two groups. No statistically significant difference was found in 1âyear and 5âyear survival between the HG (83% and 78%) and the CG (86% and 75%), P = .85. Conclusion We believe that hanging donors should be considered as conventional donors with particular caution in the final evaluation of the graft and in perioperative management
Recommended from our members
Donorâspecific HLA antibodyâmediated complement activation is a significant indicator of antibodyâmediated rejection and poor longâterm graft outcome during lung transplantation: a single center cohort study
Complement-mediated allograft injury, elicited by donor-specific HLA antibodies (DSA), is a defining pathophysiological characteristic of allograft damage. We aimed to study DSA-induced complement activation as a diagnostic marker of antibody-mediated rejection (AMR) and a risk stratification tool for graft loss in the context of lung transplantation (LT). We identified 38 DSA-positive patients whose serum samples were submitted for C3d deposition testing via the C3d assay. Among these 38 patients, 15 had AMR (DSAPos AMRPos ). Results were reported for each patient as the C3d ratio for each DSA, the immunodominant DSA, and the C3d ratio for all DSA present in a sample (C3d ratioSUM ). DSAPos AMRPos patients had higher C3d ratioSUM values (58.66 (-1.32 to 118.6) vs. 1.52 (0.30 to 2.74), P = 0.0016) and increased immunodominant C3d ratios (41.87 (1.72 to 82.02) vs. 0.69 (0.21 to 1.19), P = 0.001) when compared with DSAPos AMRNeg patients. Specificity and calculated positive predictive value of the immunodominant C3d ratio and BCMsum tests for AMR diagnosis were both 100% (CI = 17.4-100) in this cohort. Worst graft survival was associated with both immunodominant C3d ratio â„4 or C3d ratioSUM â„10 or BCMsum >7000, suggesting that the antibody composition and/or strength are the principal determinants of an HLA DSA's capacity to activate complement
Results of Lung Transplantation for Cystic Fibrosis With Selected Donors Over 65Â Years Old
International audienceLung transplantation is limited by the shortage of suitable donors. Many programs have begun to use extended criteria donors. Donors over 65Â years old are rarely reported, especially for young cystic fibrosis recipients. This monocentric study was conducted for cystic fibrosis recipients from January 2005 to December 2019, comparing two cohorts according to lung donor age (&lt;65Â years or â„65Â years). The primary objective was to assess the survival rate at 3Â years using a Cox multivariable model. Of the 356 lung recipients, 326 had donors under 65Â years, and 30 had donors over 65Â years. Donorsâ characteristics did not differ significantly in terms of sex, time on mechanical ventilation before retrieval, and partial pressure of arterial oxygen/fraction of inspired oxygen ratio. There were no significant differences in post-operative mechanical ventilation duration and incidence of grade 3 primary graft dysfunction between the two groups. At 1, 3, and 5Â years, the percentage of predicted forced expiratory volume in 1Â s (p = 0.767) and survival rate did not differ between groups (p = 0.924). The use of lungs from donors over 65Â years for cystic fibrosis recipients allows extension of the donor pool without compromising results. Longer follow-up is needed to assess the long-term effects of this practice.</jats:p
Results of Lung Transplantation for Cystic Fibrosis With Selected Donors Over 65Â Years Old
International audienceLung transplantation is limited by the shortage of suitable donors. Many programs have begun to use extended criteria donors. Donors over 65Â years old are rarely reported, especially for young cystic fibrosis recipients. This monocentric study was conducted for cystic fibrosis recipients from January 2005 to December 2019, comparing two cohorts according to lung donor age (&lt;65Â years or â„65Â years). The primary objective was to assess the survival rate at 3Â years using a Cox multivariable model. Of the 356 lung recipients, 326 had donors under 65Â years, and 30 had donors over 65Â years. Donorsâ characteristics did not differ significantly in terms of sex, time on mechanical ventilation before retrieval, and partial pressure of arterial oxygen/fraction of inspired oxygen ratio. There were no significant differences in post-operative mechanical ventilation duration and incidence of grade 3 primary graft dysfunction between the two groups. At 1, 3, and 5Â years, the percentage of predicted forced expiratory volume in 1Â s (p = 0.767) and survival rate did not differ between groups (p = 0.924). The use of lungs from donors over 65Â years for cystic fibrosis recipients allows extension of the donor pool without compromising results. Longer follow-up is needed to assess the long-term effects of this practice.</jats:p
Characteristics of Donor-Specific Antibodies Associated With Antibody-Mediated Rejection in Lung Transplantation
Although donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) are frequently found in recipients after lung transplantation (LT), the characteristics of DSA which influence antibody-mediated rejection (AMR) in LT are not fully defined. We retrospectively analyzed 206 consecutive LT patients of our center (2010â2013). DSAs were detected by using luminex single antigen beads assay and mean fluorescence intensity was assessed. Within the study population, 105 patients had positive DSA. Patients with and without AMR (AMRPos, nâ=â22, and AMRNeg, nâ=â83, respectively) were compared. AMRPos patients had significantly greater frequencies of anti-HLA DQ DSA (DQ DSA) than AMRNeg patients (95 vs 58%, respectively, pâ<â0.0001). Compared to AMRNeg patients, AMRPos patients had higher DQ DSA sum MFI [7,332 (2,067â10,213) vs 681 (0â1,887), pâ<â0.0001]. DQ DSA when associated with AMR, had more frequent graft loss and chronic lung allograft dysfunction (CLAD). These data suggest (i) that DSA characteristics clearly differ between AMRPos and AMRNeg patients and (ii) the deleterious impact of DQ DSA on clinical outcome